Publications
2021
. Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer. ASCO GU 2021. (Abstract Number: 119).
Read More > ASCO-GU Poster Presentation
2020
. The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. ENA 2020 – 32nd Symposium. (EORTC-NCI-AACR) (Abstract ID #181).
Read More > EORTC-NCI-AACR 32nd Symposium Poster. EPI-7386, a potent N-terminal domain androgen receptor inhibitor, with a favorable preclinical safety and superior in vitro/in vivo profile, in clinical development for prostate cancer. Prostate Cancer Foundation 27th Annual Scientific Retreat.
Read More > Prostate Cancer Foundation 27th Annual Scientific Retreat Poster. Pre-clinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. ESMO Virtual Congress 2020. (Poster ID #11P).
Read More > ESMO Virtual Congress 2020 Poster. Pre-clinical development of the second-generation N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. American Association for Cancer Research Virtual Annual Meeting II 2020. (Abstract ID #1953).
Read More > 2020 AACR Virtual Annual Meeting II Poster